CURRENT RESEARCH - enrolling now

1. Treatment Trial for Patients with previous, chronic Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Regenera Pharma and NORDIC are collaborating on a treatment trial to evaluate Regenera's novel drug, RPh201, an extract from a botanical source, to treat chronic Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).

Find a list of doctors for the Regenera NAION study, enrolling now.  This trial is being conducted by Neuro-Ophthalmologists in private practices and hospitals in the United States.

Read more from NORDIC on the background of this study.